Medical innovation is the key to addressing the big unmet needs in neurodegeneration, metabolic and heart disease, cancer, among many other conditions. Not only do new therapeutics and devices aimed at this diseases offer clinical promise, but they also can provide significant health economics benefits.
This combination – clinically meaningful advance coupled with sound economics – is what those of us in the life science R&D funding ecosystem focus on every day. On the venture side, figuring out how to generate returns from medical advances requires us to innovate both with regards to products and business models.
To read the full, original article click on this link: NextWave of Pharma Innovation? - Forbes
